Bio-Rad Laboratories Reports $317.8M Net Income in Q2 2025, Completes Stilla Technologies Acquisition

Bio-Rad Laboratories, Inc. reported its financial results for the second quarter and first half of 2025, revealing a net income of $317.8 million for the three months ending June 30, 2025, compared to a net loss of $2.2 billion in the same period last year. For the first half of 2025, the company recorded a net income of $381.8 million, a significant recovery from a net loss of $1.8 billion in the first half of 2024. Revenue for the second quarter increased by 2.1% to $651.6 million, while total revenue for the first half decreased slightly to $1.24 billion from $1.25 billion in the prior year.

The company experienced notable changes in its financial performance compared to the previous fiscal period. Gross profit margins decreased to 53.0% in the second quarter of 2025 from 55.6% in the same quarter of 2024, attributed to higher material costs and reduced fixed manufacturing absorption. Selling, general, and administrative expenses rose to $207.7 million, or 31.9% of sales, up from 30.5% in the prior year, primarily due to increased employee-related costs. Research and development expenses also increased to $60.5 million, reflecting higher project-related spending.

In terms of strategic developments, Bio-Rad completed the acquisition of Stilla Technologies on June 30, 2025, for a total consideration of approximately $257.9 million. This acquisition aims to enhance Bio-Rad's offerings in droplet digital PCR technology and expand its presence in new molecular testing markets. The company reported that the results of Stilla's operations post-acquisition are not yet material to its overall financial results.

Operationally, Bio-Rad's customer base remains diverse, with approximately 41% of its year-to-date 2025 consolidated net sales derived from the United States and 59% from international markets. The company noted a decrease in sales in the Asia Pacific region, primarily due to lower reimbursements for diabetes testing in China, while sales in the Americas and EMEA showed growth. The company’s employee headcount and engagement metrics were not disclosed in the filing.

Looking ahead, Bio-Rad anticipates continued challenges due to global economic conditions, including inflationary pressures and geopolitical uncertainties. The company expects these factors to impact its operations and financial performance throughout the remainder of 2025. Management remains focused on integrating the Stilla acquisition and enhancing product offerings to drive future growth, while also navigating the complexities of international regulations and market dynamics.